NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today announced it has purchased proteomics sample preparation firm Intrinsic Bioprobes for an undisclosed amount.
Based in Tempe, Ariz., Intrinsic manufactures immuno-enrichment sample prep tools for quantitative mass spectrometry. Among its offerings is the Mass Spectrometric Immunoassay, or MSIA, which allows for the enrichment of low-abundance proteins in biological samples.
The deal, Thermo Fisher said, allows it to offer customers "an enhanced solution for quantitative protein biomarker detection." Coupled with mass spectrometry, MSIA gives researchers a "complete higher-resolution view of the proteome," the company said, adding that Intrinsic's sample prep technologies with Thermo Fisher's automated sample processing, quantitative mass specs, and software "creates a complete, integrated workflow for the quantitative detection of protein biomarkers."
Chuck Kummeth, president of Thermo Fisher's laboratory consumables business, said in a statement that the purchase enhances his firm's position in the "rapidly emerging field of clinical proteomics" and better positions it to help customers "realize the promise of personalized medicine."
Thermo Fisher and Intrinsic have a relationship dating back at least one year when they announced a deal to co-develop and market a mass spec-based solution for quantitative, high-throughput, and high-resolution protein biomarker assays.
The deal also follows Thermo Fisher's recent $3.5 billion purchase of specialty diagnostics firm Phadia.